Interferon beta-1a

Home / Medicines / Betainterferon 1a

Immunomodulator indicated for the treatment of multiple sclerosis, helping to reduce relapses and to slow disease progression.

Interferon beta-1a

Active Ingredient: Interferon beta-1a

Indication for Betainterferon 1a:

Relapsing-Remitting Multiple Sclerosis (adult and pediatric use from 12 years of age) Recombinant Betainterferon 1a is indicated for the treatment of multiple sclerosis characterized by the presence of relapses, and has been shown to reduce the number and severity of such relapses, as well as to stabilize disease progression.

The indication for recombinant Betainterferon 1a and its respective dosage must be determined exclusively by the physician and should be preceded by an accurate diagnosis regarding the stage of the disease, laboratory tests, magnetic resonance imaging, and other diagnostic parameters known by the specialist treating the patient.

Single Clinical Event Suggestive of Multiple Sclerosis (adult use)
Recombinant betainterferon 1a 44 µg is also indicated for use in patients who have experienced a single clinical event that is likely to represent the first sign of multiple sclerosis.

Specifications

Type of medication:

Biological (recombinant protein).

Class/Main Target:

Immunomodulator Interferon (cytokine).

Therapeutic Area (MoA):

Neurology.

Prescription required?

Sale by prescription only.

The responsible use of medications is essential for treatment safety and efficacy. Self-medication may mask symptoms, cause adverse effects, and compromise health. Prescription medicines must be used only under the guidance of a qualified healthcare professional.